This statement seems to ignore any real value of the products…. SP won’t determine a buyout figure…. Complex valuations using discounted cash flow would be applied to determine a mathematical valuation for the products over their patent life with contingency factored in…. SP is pretty much irrelevant
Ann: HER-Vaxx Immunotherapy Patent Granted in Europe, page-62
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.9¢ |
Change
0.001(1.04%) |
Mkt cap ! $356.9M | |||
| Open | High | Low | Value | Volume |
| 4.9¢ | 4.9¢ | 4.8¢ | $84.56K | 1.735M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 60 | 7551378 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 2797268 | 18 |
View Market Depth
| Last trade - 10.36am 04/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |